{"organizations": [], "uuid": "7d46be765eb0ae3f7d9b942e0e36d7d95a2ed4fc", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-rexahn-pharmaceuticals-says-conext/brief-rexahn-pharmaceuticals-says-conext-bt-co-ltd-terminated-some-research-collaboration-agreement-on-rx-0201-clinical-development-dated-feb-6-2003-idUSFWN1PY1OO", "country": "US", "domain_rank": 408, "title": "BRIEF-Rexahn Pharmaceuticals Says Co,Next BT Co Ltd Terminated Some Research Collaboration Agreement On RX-0201 Clinical Development Dated Feb 6, 2003", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-02-09T00:09:00.000+02:00", "replies_count": 0, "uuid": "7d46be765eb0ae3f7d9b942e0e36d7d95a2ed4fc"}, "author": "", "url": "https://www.reuters.com/article/brief-rexahn-pharmaceuticals-says-conext/brief-rexahn-pharmaceuticals-says-conext-bt-co-ltd-terminated-some-research-collaboration-agreement-on-rx-0201-clinical-development-dated-feb-6-2003-idUSFWN1PY1OO", "ord_in_thread": 0, "title": "BRIEF-Rexahn Pharmaceuticals Says Co,Next BT Co Ltd Terminated Some Research Collaboration Agreement On RX-0201 Clinical Development Dated Feb 6, 2003", "locations": [], "entities": {"persons": [{"name": "rexgene", "sentiment": "none"}], "locations": [{"name": "co", "sentiment": "none"}], "organizations": [{"name": "next bt co ltd", "sentiment": "neutral"}, {"name": "brief-rexahn pharmaceuticals says co", "sentiment": "neutral"}, {"name": "rexahn pharmaceuticals inc", "sentiment": "none"}, {"name": "reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Feb 8 (Reuters) - Rexahn Pharmaceuticals Inc:\n* REXAHN PHARMACEUTICALS-ON FEB 5,CO,NEXT BT CO. LTD TERMINATED SOME RESEARCH COLLABORATION AGREEMENT ON RX-0201 CLINICAL DEVELOPMENT DATED FEB 6, 2003\n* REXAHN PHARMACEUTICALS - THE TERMINATED AGREEMENT DATED AS OF FEBRUARY 6, 2003, IS BY & BETWEEN CO AND REXGENE BIOTECH\n* REXAHN - IN TERMINATED AGREEMENT, REXGENE AGREED TO ASSIST CO IN RESEARCH,DEVELOPMENT &CLINICAL TRIALS NECESSARY FOR REGISTRATION IN ASIA OF RX-0201\n* REXAHN - TERMINATED AGREEMENT WAS TERMINATED TO ALLOW CO TO TRANSITION TO A NEW DEVELOPMENT STRATEGY FOR RX-0201 & OTHER DRUG CANDIDATES AMONG OTHERS Source text: [ bit.ly/2EtkwFz ] Further company coverage:\n ", "external_links": [], "published": "2018-02-09T00:09:00.000+02:00", "crawled": "2018-02-09T00:22:48.004+02:00", "highlightTitle": ""}